One strategy is to activate the CD40–CD40L interaction in APCs and enhance the effect of cytotoxic T cells against tumor antigens to enhance the host immune response against tumor cells; indeed, the CD40 agonist has been found to have independent T-cell anti-tumor effects by depleting the tumor stroma [130,131]. The gene discussed is CD40; the disease is neoplasm.